BioSpace News Archive

CASI Pharmaceuticals, Inc. reported business and financial results for the third quarter ended September 30, 2023.

908 Devices Inc. announced that it has expanded access to its leading trace detection technology in its handheld MX908 device through the addition of a weatherproof, digital communications port, thereby enabling companies to integrate the device into their systems to enhance the safety of their users and the public.

Silence Therapeutics plc reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

NeoGenomics, Inc., a leading oncology testing services company, announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.

Ludwig Enterprises, Inc. announced that the U.S. Securities and Exchange Commission has declared the Company’s Registration Statement on Form S-1 effective as of November 8, 2023.

SAB Biotherapeutics, Inc. today reported financial results for the third quarter ended October 31, 2023, and provided a company update.

Atsena Therapeutics today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1).

Qu Biologics Inc. is pleased to announce that its Phase 2 clinical trial in late-stage colon cancer, PERIOP-06, was awarded CAD$400,000 in grant funding by the Accelerating Clinical Trial Canadian Consortium.

Spectral Medical Inc. announced the publication of its Tigris trial methods paper in Critical Care, which discusses the use of Bayesian methods in clinical trial design.